Currently, cilengitide is being evaluated in a recently completed pivotal, randomized Phase III study (Cilengitide in Combination with Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Phase III Randomized Clinical Trial (CENTRIC)) for newly diagnosed Glioblastoma Multiforme with MGMT promoter methylation [38]. Here, MGMT is linked to glioblastoma.